Disposition and mass balance of [14C]Vernakalant after single intravenous and oral doses in healthy volunteers

Drug Metabolism Letters

Volumn 5, Issue 2, 2011, Pages 114-125

  Mao, Z L ^a,c   Alak, A ^a   Wheeler, J J ^b   Keirns, J ^a  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^b Cardiome Pharma Corp   (Canada)

^c Impax Pharmaceuticals   (United States)

Author keywords

Antiarrhythmic drug; CYP2D6 genotype; Mass balance; Metabolism; Pharmacokinetics; RSD1235; Vernakalant hydrochloride

Indexed keywords

CARBON 14; CYTOCHROME P450 2D6; DRUG METABOLITE; VERNAKALANT;

ADULT; ANUS FISSURE; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TOLERABILITY; DYSGEUSIA; FECES ANALYSIS; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; MASS BALANCE; NORMAL HUMAN; OPEN STUDY; PARALLEL DESIGN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE; SINUS RHYTHM; URINARY EXCRETION; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANISOLES; ANTI-ARRHYTHMIA AGENTS; CARBON RADIOISOTOPES; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PYRROLIDINES;

EID: 79954482597     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231211795305249     Document Type: Article

References (22)

1. Go, A.S.; Hylek, E.M.; Phillips, K.A.; Chang, Y.; Henault, L.E.; Selby, J.V.; Singer, D.E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001. 285(18), 2370-2375.
2. Wolf, P.A.; Abbott, R.D.; Kannel, W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991. 22(8), 983-988.
3. Benjamin, E.J.; Wolf, P.A.; D'Agostino, R.B.; Silbershatz, H.; Kannel, W.B.; Levy, D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation, 1998. 98(10), 946-952.
4. Coyne, K.S.; Paramore, C.; Grandy, S.; Mercader, M.; Reynolds, M.; Zimetbaum, P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health, 2006. 9(5), 348-356.
5. Dorian, P.; Jung, W.; Newman, D.; Paquette, M.; Wood, K.; Ayers, G.M.; Camm, J.; Akhtar, M.; Luderitz, B. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol, 2000. 36(4), 1303-1309.
6. Wakai, A.; O'Neill, J.O. Emergency management of atrial fibrillation. Postgrad Med J, 2003. 79(932), 313-319.
7. Nichol, G.; McAlister, F.; Pham, B.; Laupacis, A.; Shea, B.; Green, M.; Tang, A.; Wells, G. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart, 2002. 87(6), 535-543.
8. Fedida, D.; Orth, P.M.; Chen, J.Y.; Lin, S.; Plouvier, B.; Jung, G.; Ezrin, A.M.; Beatch, G.N. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol, 2005. 16(11), 1227-1238.
9. Beatch, G.N.; Lin, S.-P.; Hesketh, C.; Johnson, B.D.; Ezrin, A.M.; Fedida, D. Electrophysiological mechanism of RSD1235, a new atrial fibrillation converting drug [abstract 400]. in Circulation. 2003.
10. Roy, D.; Rowe, B.H.; Stiell, I.G.; Coutu, B.; Ip, J.H.; Phaneuf, D.; Lee, J.; Vidaillet, H.; Dickinson, G.; Grant, S.; Ezrin, A.M.; Beatch, G.N. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol, 2004. 44(12), 2355-2361.
11. Torp-Pedersen, C.; Raev, D.; Georgiev, P.; Navratil, J.; Nagy, A.; Blomstrom, P.; Karpenko, Y.; Faulkner, J.; Dickinson, G.; Beatch, G.N.; Investigators, o.b.o.V.o. Oral vernakalant (RSD1235-SR) prevents recurrence of atrial fibrillation following cardioversion [abstract P-2538]. Eur Heart J, 2007. 28(suppl 1): 401.
12. Torp-Pedersen, C.; Karpenko, Y.; Raev, D.; Kaik, J.; Dickinson, G.; Mangal, B.; Beatch, G.N. Oral vernakalant for the Prevention of Atrial Fibrillation Recurrence Post-Cardioversion. Eur Heart J, 2009. 30(suppl 1): 450
13. Roy, D.; Pratt, C.M.; Torp-Pedersen, C.; Wyse, D.G.; Toft, E.; Juul-Moller, S.; Nielsen, T.; Rasmussen, S.L.; Stiell, I.G.; Coutu, B.; Ip, J.H.; Pritchett, E.L.; Camm, A.J. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation, 2008. 117(12), 1518-1525.
14. Kowey, P.R.; Dorian, P.; Mitchell, L.B.; Pratt, C.M.; Roy, D.; Schwartz, P.J.; Sadowski, J.; Sobczyk, D.; Bochenek, A.; Toft, E. Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation Following Cardiac Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial. Circulation: Arrhythmia and Electrophysiology, 2009. 2(6), 652-659 Epub.
15. Pratt, C.M.; Roy, D.; Torp-Pedersen, C.; Wyse, D.G.; Toft, E.; Juul-Moller, S.; Retyk, E.; Drenning, D.H. Usefulness of vernakalant hydrochloride for rapid conversion of atrial fibrillation. American Journal of Cardiology, 2010. In press.
16. Stiell, I.G; Roos, J.S; Kavanagh, K.M., Dickinson, G. A Multicenter, Open-Label Study of Vernakalant for the Conversion of Atrial Fibrillation to Sinus Rhythm. American Heart Journal, 2010. 159(6), 1095-101.
17. Kirchheiner, J.; Seeringer, A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta, 2007. 1770(3), 489-494.
18. Bertilsson, L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet, 1995. 29(3), 192-209.
19. Mizutani, T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev, 2003. 35(2-3), 99-106.
20. Kroemer, H.K.; Klotz, U. Glucuronidation of drugs. A reevaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet, 1992. 23(4), 292-310.
21. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharm Res, 1993. 10(7), 1093-1095.
22. Mao, Z.L.; Wheeler, J.J.; Clohs, L.; Beatch, G.N.; Keirns, J. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol, 2009. 49(1), 17-29.